MX339077B - Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas. - Google Patents

Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas.

Info

Publication number
MX339077B
MX339077B MX2011011190A MX2011011190A MX339077B MX 339077 B MX339077 B MX 339077B MX 2011011190 A MX2011011190 A MX 2011011190A MX 2011011190 A MX2011011190 A MX 2011011190A MX 339077 B MX339077 B MX 339077B
Authority
MX
Mexico
Prior art keywords
methods
bacterial infection
pulmonary
quinolones
fluoro
Prior art date
Application number
MX2011011190A
Other languages
English (en)
Other versions
MX2011011190A (es
Inventor
Mike Dudley
David Griffith
Olga Rodny
Original Assignee
Mpex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43011488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339077(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mpex Pharmaceuticals Inc filed Critical Mpex Pharmaceuticals Inc
Publication of MX2011011190A publication Critical patent/MX2011011190A/es
Publication of MX339077B publication Critical patent/MX339077B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen en la presente métodos para tratar una infección bacteriana pulmonar que comprende el desarrollo de bacterias bajo condiciones anaeróbicas utilizando un antibiótico de fluoroquinolona. El antibiótico de fluoroquinolona puede por ejemplo, ser levofloxacina o ofloxacina. También se describen métodos para inhibir el desarrollo de bacterias bajo condiciones anaeróbicas al exponer las bacterias a una cantidad de antibiótico de fluoroquinolona efectiva para inhibir el desarrollo de dichas bacterias.
MX2011011190A 2009-04-24 2010-04-22 Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas. MX339077B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17262509P 2009-04-24 2009-04-24
PCT/US2010/032128 WO2010124141A1 (en) 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoro-quinolones

Publications (2)

Publication Number Publication Date
MX2011011190A MX2011011190A (es) 2012-02-13
MX339077B true MX339077B (es) 2016-05-10

Family

ID=43011488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011190A MX339077B (es) 2009-04-24 2010-04-22 Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas.

Country Status (28)

Country Link
US (2) US20120035166A1 (es)
EP (1) EP2421539B1 (es)
JP (2) JP6179844B2 (es)
KR (1) KR20120034626A (es)
CN (2) CN107050032A (es)
AU (1) AU2010238765B2 (es)
BR (1) BRPI1006626B8 (es)
CA (1) CA2759874C (es)
CL (1) CL2011002649A1 (es)
CO (1) CO6450642A2 (es)
CY (1) CY1122525T1 (es)
DK (1) DK2421539T3 (es)
ES (1) ES2755754T3 (es)
HR (1) HRP20191951T1 (es)
HU (1) HUE046595T2 (es)
IL (1) IL215777A (es)
LT (1) LT2421539T (es)
MX (1) MX339077B (es)
MY (1) MY178871A (es)
NZ (1) NZ596245A (es)
PL (1) PL2421539T3 (es)
PT (1) PT2421539T (es)
RU (1) RU2535056C2 (es)
SG (3) SG175288A1 (es)
SI (1) SI2421539T1 (es)
SM (1) SMT201900645T1 (es)
WO (1) WO2010124141A1 (es)
ZA (1) ZA201107903B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CA2739897C (en) 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
SI2473170T1 (sl) 2009-09-04 2019-10-30 Horizon Orphan Llc Uporaba aerosoliziranega levofloksacina za zdravljenje cistične fibroze
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
WO2014152326A1 (en) * 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
JP6966835B2 (ja) * 2016-02-05 2021-11-17 ホライズン オーファン リミテッド ライアビリティ カンパニー 嚢胞性線維症のためのフルオロキノロン製剤
CN108849939B (zh) * 2018-07-31 2021-02-19 广东省农业科学院植物保护研究所 盐酸左氧氟沙星在制备用于防治烟草青枯病的农药制剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530704A (ja) * 2002-03-05 2005-10-13 トランセイブ， インク． 細胞内感染を予防及び治療するための吸入システム
RU2255757C1 (ru) * 2004-06-22 2005-07-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Пептидное соединение, восстанавливающее функцию органов дыхания
MX359219B (es) * 2005-05-18 2018-09-19 Raptor Pharmaceuticals Inc Fluoroquinolonas aerosolizadas y sus usos.
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
JP5727927B2 (ja) * 2008-05-15 2015-06-03 ノバルティス アーゲー フルオロキノロンの肺送達
CA2739897C (en) * 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics

Also Published As

Publication number Publication date
JP2016053041A (ja) 2016-04-14
HUE046595T2 (hu) 2020-03-30
KR20120034626A (ko) 2012-04-12
US20210015811A1 (en) 2021-01-21
SI2421539T1 (sl) 2019-12-31
RU2011145430A (ru) 2013-05-27
EP2421539A4 (en) 2014-01-29
DK2421539T3 (da) 2019-11-18
NZ596245A (en) 2013-11-29
SMT201900645T1 (it) 2020-01-14
MY178871A (en) 2020-10-21
CA2759874C (en) 2016-11-08
CN107050032A (zh) 2017-08-18
LT2421539T (lt) 2019-12-10
JP6179844B2 (ja) 2017-08-16
ZA201107903B (en) 2013-01-30
CL2011002649A1 (es) 2012-06-22
BRPI1006626B8 (pt) 2021-05-25
PT2421539T (pt) 2019-11-22
ES2755754T3 (es) 2020-04-23
SG10201811494SA (en) 2019-01-30
SG175288A1 (en) 2011-11-28
JP6228580B2 (ja) 2017-11-08
HRP20191951T1 (hr) 2021-05-14
EP2421539B1 (en) 2019-10-23
BRPI1006626A2 (pt) 2020-07-28
CA2759874A1 (en) 2010-10-28
CN102427815A (zh) 2012-04-25
WO2010124141A1 (en) 2010-10-28
JP2012524811A (ja) 2012-10-18
CO6450642A2 (es) 2012-05-31
AU2010238765A1 (en) 2011-11-10
BRPI1006626B1 (pt) 2021-05-11
US20120035166A1 (en) 2012-02-09
CY1122525T1 (el) 2021-01-27
EP2421539A1 (en) 2012-02-29
MX2011011190A (es) 2012-02-13
PL2421539T3 (pl) 2020-02-28
SG10201403512TA (en) 2014-08-28
IL215777A (en) 2017-09-28
IL215777A0 (en) 2012-01-31
AU2010238765B2 (en) 2014-12-18
RU2535056C2 (ru) 2014-12-10

Similar Documents

Publication Publication Date Title
CO6450642A2 (es) Métodos para tratar una infección bacteriana pulmonar utilizando fluoro-quinolonas
NZ593111A (en) Antibacterial compounds
MY174523A (en) ?-lactamase inhibitor and process for preparing the same
ECSP11010980A (es) Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
BR112016020333A2 (pt) compostos orgânicos de monobactam para o tratamento de infecções bacterianas
CO2019002624A2 (es) Compuestos antibióticos
AR079582A1 (es) Proceso de biodegradacion empleando composicion microbiana
CL2011000939A1 (es) Compuestos derivados de cefalosporinas sustituidas por un grupo catecol, con actividad antimicrobiana contra bacterias gram negativo que producen betalactamasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades infecciosas.
DOP2010000218A (es) Inhibidores de beta-lactamasa
WO2013184755A3 (en) Seca inhibitors and methods of making and using thereof
CL2011002818A1 (es) Composicion de leche para el crecimiento que comprende microorganismos probioticos; uso de dicha composicion para preparar medicamento util para prevenir o tratar trastornos inflamatorios.
MX2013011526A (es) Derivados de isoxazol utiles como agentes antibacteriales .
CR20170260A (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
EA201100874A1 (ru) Соединения для лечения рака
EA201390639A1 (ru) Производные 2-пиперазин-1-ил-4н-1,3-бензотиазин-4-она и их применение для лечения инфекций у млекопитающих
CO2022005107A2 (es) Bacterias productoras de serotonina
FI20116316L (fi) Matriisi ja koostumus grampositiivisten bakteerien mikrobiviljelyyn
WO2012103295A3 (en) Small molecule rnase inhibitors and methods of use
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
BR112012024999A2 (pt) combinação e uso
CR10998A (es) Macrolidos
MX2017004632A (es) Mejoras en y relacionadas con el tratamiento del agua, en particular para inhibir el crecimiento de microorganismos.
AR087586A1 (es) Sistema enzimatico
BR112017008101A2 (pt) composto, composição farmacêutica, métodos para inibir o dnae bacteriano e para tratar uma infecção, e, uso de um composto.
NO20101313L (no) Fremgangsmate for a hemme bakterievekst

Legal Events

Date Code Title Description
FG Grant or registration